TEL AVIV - Peregrine Ventures, an Israeli venture capital fund focused on medical technology, said on Monday it closed its fourth fund, raising $115 million.Peregrine said its partners include institutional and private equity investors from Israel, the United States, Europe and Australia. Peregrine 4 will invest in early and late stage rounds of medical technology startups. Peregrine now has over $200 million under management, and an equal amount available for co-investment, follow-on, and late stage investments in its portfolio companies from Peregrine 1, 2, and 3. console.log("catid body is "+catID);if(catID==120){document.getElementsByClassName("divConnatix")[0].style.display ="none";var script = document.createElement('script'); script.src = 'https://player.anyclip.com/anyclip-widget/lre-widget/prod/v1/src/lre.js'; script.setAttribute('pubname','jpostcom'); script.setAttribute('widgetname','0011r00001lcD1i_12258'); document.getElementsByClassName('divAnyClip')[0].appendChild(script);}else if(catID!=69 && catID!=2){ document.getElementsByClassName("divConnatix")[0].style.display ="none"; var script = document.createElement('script'); script.src = 'https://static.vidazoo.com/basev/vwpt.js'; script.setAttribute('data-widget-id','60fd6becf6393400049e6535'); document.getElementsByClassName('divVidazoo')[0].appendChild(script); }The firm has completed 10 exits totalling more than $2 billion in cumulative value.“There is a huge demand, and opportunity, in medical technologies in Israel and foreign investors recognise this,” Peregrine managing partner Eyal Lifschitz said.